Cover Image

Structural basis of Naa20 activity towards a canonical NatB substrate

N-terminal acetylation is one of the most common protein modifications in eukaryotes and is carried out by N-terminal acetyltransferases (NATs). It plays important roles in protein homeostasis, localization, and interactions and is linked to various human diseases. NatB, one of the major co-translat...

Full description

Saved in:
Bibliographic Details
Main Authors: Layer, Dominik Christian (Author) , Kopp, Jürgen (Author) , Fontanillo, Miriam (Author) , Köhn, Maja (Author) , Lapouge, Karine (Author) , Sinning, Irmgard (Author)
Format: Article (Journal)
Language:English
Published: 04 January 2021
In: Communications biology
Year: 2021, Volume: 4, Pages: 1-12
ISSN:2399-3642
DOI:10.1038/s42003-020-01546-4
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s42003-020-01546-4
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s42003-020-01546-4
Get full text
Author Notes:Dominik Layer, Jürgen Kopp, Miriam Fontanillo, Maja Köhn, Karine Lapouge & Irmgard Sinning
Description
Summary:N-terminal acetylation is one of the most common protein modifications in eukaryotes and is carried out by N-terminal acetyltransferases (NATs). It plays important roles in protein homeostasis, localization, and interactions and is linked to various human diseases. NatB, one of the major co-translationally active NATs, is composed of the catalytic subunit Naa20 and the auxiliary subunit Naa25, and acetylates about 20% of the proteome. Here we show that NatB substrate specificity and catalytic mechanism are conserved among eukaryotes, and that Naa20 alone is able to acetylate NatB substrates in vitro. We show that Naa25 increases the Naa20 substrate affinity, and identify residues important for peptide binding and acetylation activity. We present the first Naa20 crystal structure in complex with the competitive inhibitor CoA-Ac-MDEL. Our findings demonstrate how Naa20 binds its substrates in the absence of Naa25 and support prospective endeavors to derive specific NAT inhibitors for drug development.
Item Description:Gesehen am 08.02.2021
Physical Description:Online Resource
ISSN:2399-3642
DOI:10.1038/s42003-020-01546-4

Similar Items